Alexion Pharmaceuticals Inc. (ALXN) Board Of Directors Appoints New Chairman And Creates The New Position Of Lead Independent Director

Alexion Pharmaceuticals Inc. (ALXN) Board Of Directors Appoints New Chairman And Creates The New Position Of Lead Independent Director

CHESHIRE, Conn.--(BUSINESS WIRE)--The Board of Directors of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Leonard Bell, M.D. has been appointed Chairman of the Board of Directors. Dr. Bell, principal founder of Alexion, continues to serve as Chief Executive Officer of the Company. Additionally, R. Douglas Norby has been appointed to the newly created Board position of Lead Independent Director. Mr. Norby, who was voted Lead Independent Director by the other independent members of the Board, has been a Director of Alexion since September 1999. Mr. Norby currently serves as Chair of the Audit Committee, a member of the Nominating and Corporate Governance Committee, and a member of the Risk and Strategy Committee. Both of these appointments follow the passing of Max Link, Ph.D., as announced earlier this week, who served as the Chairman of the Board of Directors of Alexion since December 2002 and as a member of the Board since the Company's inception in 1992. 

Suggested Articles

No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.

Merck has a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S.

Acceleron has chalked up another phase 2 flop as its pipeline thins a little more.